Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 5Mouth Neoplasms 3Carcinoma 3Squamous Cell Carcinoma of Head and Neck 2Skin Neoplasms 2Recurrence 2Mycosis Fungoides 2Lymphoma, T-Cell 2Lymphoma, Large-Cell, Anaplastic 2Lymphoma, B-Cell 2Laryngeal Neoplasms 2Vaccinia 1Sinonasal Squamous Cell Carcinoma 1Sarcoma 1Resectable Non-small Cell Lung Cancer 1Ovarian Neoplasms 1Oropharyngeal Neoplasms 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Multiple Myeloma 1Melanoma 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lung Neoplasms 1Leukemia, Myeloid, Acute 1Immunoblastic Lymphadenopathy 1

Interventions

Bevacizumab 12olaparib 10Paclitaxel 10Carboplatin 10liposomal doxorubicin 7Specimen Handling 7Magnetic Resonance Spectroscopy 6mirvetuximab soravtansine 4Topotecan 4Taxes 4Immunoglobulin G 4Gemcitabine 4Disulfides 4Biopsy 4pembrolizumab 3cediranib 3Oxaliplatin 2Doxorubicin 21-dodecylpyridoxal 2tremelimumab 1trastuzumab deruxtecan 1sotorasib 1sarilumab 1palbociclib 1niraparib 1nilotinib 1neratinib 1irinotecan sucrosofate 1ipatasertib 1dehydroftorafur 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × cemiplimab × 30 days × Clear all
NCT06787612 2026-05-20

Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

Regeneron Pharmaceuticals

Phase 2 Recruiting
220 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡